SCHEMBL3384874

SCHEMBL3384874

O=C(N[C@@H](CCO)c1ccccc1)[C@@H]1SCCN1S(=O)(=O)c1ccc(-c2ccccc2F)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 1/20 0.59
HSD11B1 P28845 8/20 0.42
PAX8 Q06710 1/20 0.38
ALDH1A1 P00352 1/20 0.37
GRIA4 P48058 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
PRKACA P17612 1/20 0.36
CDK8 P49336 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
PRKX P51817 1/20 0.36
PRKCQ Q04759 1/20 0.36
ROCK1 Q13464 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3382831 0.95 PTGFR (0.64) PTGFRHSD11B1MMP2ATM
SCHEMBL3386001 0.91 PTGFR (0.55) PTGFRHSD11B1PAX8ALDH1A1GRIA4
SCHEMBL3384707 0.91 PTGFR (0.51) PTGFRHSD11B1PAX8ALDH1A1GRIA4
SCHEMBL3382653 0.91 PTGFR (0.64) PTGFRHSD11B1ALDH1A1MMP2MMP9
SCHEMBL3382557 0.91 PTGFR (0.64) PTGFRHSD11B1ALDH1A1MMP2MMP9
SCHEMBL3382579 0.91 PTGFR (0.64) PTGFRHSD11B1ALDH1A1MMP2MMP9
SCHEMBL3383620 0.91 PTGFR (0.64) PTGFRHSD11B1ALDH1A1MMP2MMP9
SCHEMBL3386103 0.91 PTGFR (0.64) PTGFRHSD11B1ALDH1A1MMP2MMP9
SCHEMBL3381107 0.89 PTGFR (0.73) PTGFRHSD11B1MMP2MMP9
SCHEMBL3382048 0.89 PTGFR (0.73) PTGFRHSD11B1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024294-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR XOMA (US) LLC 2024-01-25 US disclosed
US-20230372306-A1 COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR XOMA (US) LLC 2023-11-23 US disclosed
US-11534428-B1 Compositions and methods for delaying the incidence of labor XOMA (US) LLC (US) 2022-12-27 US disclosed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor MERCK SERONO SA (CH) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372306-A1 COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR PGF, TRPV2, TRPV3 PTGFR 9/4885HSD11B1 2075/4885PAX8 4732/4885
US-20240024294-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR PGF, PTGS1, PTGIR PTGFR 7/4885HSD11B1 2481/4885PAX8 4294/4885
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885HSD11B1 2095/4885PAX8 3909/4885
US-11534428-B1 Compositions and methods for delaying the incidence of labor PGF, TRPV2, TRPV3 PTGFR 9/4885HSD11B1 2075/4885PAX8 4732/4885
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885HSD11B1 2095/4885PAX8 3909/4885
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor TBXA2R, CNR2, PTGDR PTGFR 16/4885HSD11B1 2705/4885PAX8 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.